Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666705 · ClinicalTrials.gov registry record · Phase 4
A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
A Phase 4 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT00666705: Completed Phase 4 study, sponsored by ViiV Healthcare.
NCT00666705 is a Phase 4 study that has completed, run by ViiV Healthcare. The registered enrollment target is 18 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666705, a Phase 4 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.
Primary Outcome
Effect of raltegravir on pharmacokinetics of maraviroc (comparison of AUCτ of raltegravir co-administered with maraviroc (Test) versus maraviroc administered alone (Reference)). Pharmacokinetics were assessed on Day 11 (maraviroc) and Day 14 (maraviroc and raltegravir).
Interventions
- DRUG Maraviroc
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 4 |
What the finished NCT00666705 record still lists
NCT00666705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Maraviroc is the first listed.
NCT00666705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00666705 about?
NCT00666705 is a clinical study titled "A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects". An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.
What is the current status of trial NCT00666705?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2008-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00666705?
The interventions under investigation include: Maraviroc (DRUG), Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00666705?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00666705's enrollment target sits among peer trials
18 1842nd of 2000 higher than 147 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia